GlassScriptPhysician profile
Christopher S Cronin
NPI 1043204597
$11,052.41
in general payments reported to CMS, 2019-2025
37 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $350 · 2021: $7,688 · 2022: $527 · 2023: $1,373 · 2024: $284 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Travel and Lodging: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.75 |
| Travel and Lodging | $865.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,615.20 | 2019-2024 | Da Vinci Surgical System |
| Davol INC. | $418.58 | 2019-2023 | Phasix Mesh |
| Ethicon US, LLC | $255.02 | 2019-2022 | |
| Endologix LLC | $252.49 | 2019-2024 | Torus Stent Graft System, Endocross Device |
| Medtronic, INC. | $213.66 | 2021-2024 | Eea, Versastep, V-Loc 180 |
| W. L. Gore & Associates, INC. | $128.02 | 2021-2024 | Gore Enform Preperitoneal Biomaterial |
| Medical Device Business Services, INC. | $121.84 | 2020 | |
| Smith+Nephew, INC. | $109.24 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home, Pico 7 |
| Baxter Healthcare | $72.16 | 2019-2022 | |
| Stryker Corporation | $71.55 | 2020-2023 | N/A |
| Takeda Pharmaceuticals U.S.A., INC. | $56.49 | 2020-2021 | |
| Convatec INC. | $56.09 | 2019-2021 | |
| Aroa Biosurgery Incorporated | $55.09 | 2025 | |
| Shire North American Group INC | $54.93 | 2019 | |
| Kerecis Limited | $48.06 | 2022-2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $46.06 | 2019 | |
| Polynovo North America LLC | $44.44 | 2024 | Novosorb Btm |
| Cumberland Pharmaceuticals, INC. | $37.24 | 2020-2023 | Caldolor |
| Solventum Corporation | $36.52 | 2024-2025 | Prevena, V.A.C. Veraflo, V.A.C.Instill |
| Heron Therapeutics, INC. | $34.68 | 2021 | |
| Fresenius Kabi USA, LLC | $30.88 | 2021 | |
| Depuy Synthes Sales INC. | $30.75 | 2020 | |
| Tela Bio, INC. | $24.86 | 2019-2021 | |
| Allergan, INC. | $23.73 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.89 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $20.88 | 2019 | |
| Hologic Sales and Service, LLC | $20.12 | 2024 | Localizer |
| Ovik Health, LLC | $19.13 | 2020 | |
| Baudax Bio INC. | $17.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.63 | 2021 | |
| Braintree Laboratories, INC. | $15.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.49 | 2019 | |
| Covidien LP | $14.25 | 2020 | |
| Tactile Systems Technology INC | $13.72 | 2019 | |
| Kci USA, INC. | $12.81 | 2022 | |
| Abbott Laboratories | $12.36 | 2021 | |
| 3m Company | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cronin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.